文献速递眼底病与葡萄膜炎

美国新生血管性年龄相关性黄斑变性治疗中雷珠单抗与贝伐珠单抗使用的地理与人口学差异

Geographic and Demographic Variation in Use of Ranibizumab Versus Bevacizumab for Neovascular Age-related Macular Degeneration in the United States.
PubMed 文献 · Am J Ophthalmol · 2017-10-27

该回顾性队列研究利用美国联邦医疗保险(Medicare)100%索赔数据,分析195,812例新生血管性年龄相关性黄斑变性(AMD)受益人中首次接受雷珠单抗或贝伐珠单抗治疗的人口学与地理差异。总体上35%的受益人首先接受雷珠单抗,该比例在306个医院转诊区间从0.9%至84.6%不等(中位数33%,四分位距17%-49%)。2009年较2006年接受雷珠单抗的调整比值比(aOR)为0.39(P<.001),黑人受益人较非黑人接受雷珠单抗的可能性低45%(P<.0001)。

要点

  • 总体35%的新生血管性AMD受益人首先接受雷珠单抗,各医院转诊区间比例从0.9%至84.6%不等。
  • 2009年较2006年接受雷珠单抗的aOR为0.39(P<.001),随时间的推移可能性下降。
  • 黑人受益人较非黑人接受雷珠单抗的可能性低45%(P<.0001),城市地区、较高收入邮编及新英格兰和东南中部普查区与接受雷珠单抗的 odds 增加相关。

核心结论

  • 美国Medicare受益人中,新生血管性AMD初始治疗选择贝伐珠单抗 vs 雷珠单抗的 odds 在地理和人口学组间差异显著。
  • 2009年 vs 2006年,相对较少患者初始接受雷珠单抗治疗新生血管性AMD。

研究设计与样本

  • 回顾性队列研究,使用Medicare索赔数据100%样本,纳入2006年7月1日至2009年6月30日间有新生血管性AMD索引索赔的受益人N=195,812,判定初诊后首先接受雷珠单抗还是贝伐珠单抗。

主要发现

  • 总体首先接受雷珠单抗的受益人比例为35%,在306个美国医院转诊区间中从0.9%至84.6%不等(中位数33%,四分位距17%-49%)。
  • 基于分层 logistic 回归模型,接受雷珠单抗的可能性随时间下降(2009年 vs 2006年治疗比较的aOR=0.39,P<.001)。
  • 控制治疗年份后,黑人受益人较非黑人接受雷珠单抗的可能性低45%(P<.0001)。
  • 居住在城市地区的受益人(aOR vs 孤立农村城镇=1.12,P<.001)、居住在中位收入较高邮编的受益人、以及居住在新英格兰和东南中部普查区的受益人(aOR vs 太平洋普查区分别=5.57,P<.001;aOR=3.58,P<.001)接受雷珠单抗的 odds 增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine demographic and geographic variation in the use of ranibizumab and bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) among Medicare beneficiaries. DESIGN: Retrospective cohort study. METHODS: Using a 100% sample of Medicare claims data, we evaluated Medicare beneficiaries (N = 195 812) with an index claim for neovascular AMD between July 1, 2006, and June 30, 2009, to determine whether beneficiaries first received ranibizumab or bevacizumab following initial diagnosis. RESULTS: The overall proportion of beneficiaries that first received ranibizumab for neovascular AMD was 35%, and varied significantly (0.9%-84.6%) across the 306 US hospital referral regions (median = 33%, interquartile range = 17%-49%). Based on hierarchical logistic regression models, the likelihood of receiving ranibizumab declined over time (adjusted odds ratio (aOR) comparing treatment in 2009 vs 2006 = 0.39, P < .001). After we controlled for year of treatment, black beneficiaries were 45% less likely to receive ranibizumab compared to non-blacks (P < .0001). Beneficiaries residing in urban areas (aOR vs isolated rural towns = 1.12, P < .001), in zip codes with higher median incomes, and in the New England and East South Central census regions (aOR vs Pacific census region = 5.57, P < .001; aOR = 3.58, P < .001, respectively) had increased odds of receiving ranibizumab. CONCLUSIONS: The odds of receiving bevacizumab vs ranibizumab as initial therapy for neovascular AMD among US Medicare beneficiaries varied substantially across geographic and demographic groups. Relatively fewer patients received ranibizumab for initial neovascular AMD treatment in 2009 vs 2006. Future research should study the drivers of variation in utilization of these interventions, the extent this variation indicates differential access to these agents, and whether treatment choice impacts patient outcomes.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Gower EW, Stein JD, Shekhawat NS, et al. Geographic and Demographic Variation in Use of Ranibizumab Versus Bevacizumab for Neovascular Age-related Macular Degeneration in the United States. Am J Ophthalmol. 2017. PMID: 29106914. doi:10.1016/j.ajo.2017.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。